Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Test of Sensitization

Test Result Further Supports the AC5™ Biocompatibility Profile FRAMINGHAM, MA OTCQB, ARTH, (Marketwired Sep 8, 2015) Arch Therapeutics, Inc. (OTCQB: ARTH) ( Arch or the Company ), developer of the AC5 Surgical Hemostatic Device™ ( AC5™ ), obtained favorable data from a preclinical toxicology test for AC5™ showing that the device did not cause sensitizing reactions in animals and is considered a non-sensitizer. The test, called the Maximization Test, is a standardized test of contact sensitization and is performed in animals as a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support application


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: